174 related articles for article (PubMed ID: 29689141)
1. Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC).
Nellesen D; Dea K; Guerin A; Culver KW; Mutebi A; Dalal A
Am J Manag Care; 2018 Feb; 24(2 Spec No.):SP37-SP42. PubMed ID: 29689141
[No Abstract] [Full Text] [Related]
2. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.
VanderLaan PA; Chen Y; DiStasio M; Rangachari D; Costa DB; Heher YK
Clin Lung Cancer; 2018 Sep; 19(5):e589-e590. PubMed ID: 29798809
[No Abstract] [Full Text] [Related]
3. Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.
Planchard D; Remon J; Nowak F; Soria JC
Am Soc Clin Oncol Educ Book; 2017; 37():12-17. PubMed ID: 28561640
[No Abstract] [Full Text] [Related]
4. The future of oncology treatment through diagnostic testing.
Oakley G
MLO Med Lab Obs; 2013 Dec; 45(12):38. PubMed ID: 24409595
[No Abstract] [Full Text] [Related]
5. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
Riely GL
J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
[TBL] [Abstract][Full Text] [Related]
6. Section IV: non-small cell lung cancer and malignant melanoma.
Fisher KE; Pillai RN; Kudchadkar RR; Rossi MR
Curr Probl Cancer; 2014; 38(5):180-98. PubMed ID: 25281457
[No Abstract] [Full Text] [Related]
7. The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer.
Ross K; Pailler E; Faugeroux V; Taylor M; Oulhen M; Auger N; Planchard D; Soria JC; Lindsay CR; Besse B; Vielh P; Farace F
Expert Rev Mol Diagn; 2015; 15(12):1605-29. PubMed ID: 26564313
[TBL] [Abstract][Full Text] [Related]
8. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
9. Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration.
Casadio C; Guarize J; Donghi S; Di Tonno C; Fumagalli C; Vacirca D; Dell'Orto P; De Marinis F; Spaggiari L; Viale G; Barberis M
Am J Clin Pathol; 2015 Oct; 144(4):629-34. PubMed ID: 26386084
[TBL] [Abstract][Full Text] [Related]
10. NSCLC molecular testing in Central and Eastern European countries.
Ryska A; Berzinec P; Brcic L; Cufer T; Dziadziuszko R; Gottfried M; Kovalszky I; Olszewski W; Oz B; Plank L; Timar J
BMC Cancer; 2018 Mar; 18(1):269. PubMed ID: 29523116
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutation testing for squamous cell lung carcinoma.
Liam CK; Leow HR; Pang YK
J Thorac Oncol; 2013 Dec; 8(12):e114. PubMed ID: 24389448
[No Abstract] [Full Text] [Related]
12. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
13. Molecular diagnostics in advanced NSCLC: trying to maximize a non-ideal situation.
Lim EH; Tan P
J Thorac Oncol; 2007 Aug; 2(8):782. PubMed ID: 17762350
[No Abstract] [Full Text] [Related]
14. First-line therapy of mutated non-small cell lung cancer: an update.
Stöhlmacher-Williams J
Onkologie; 2012; 35(5):293-9. PubMed ID: 22868512
[TBL] [Abstract][Full Text] [Related]
15. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
[TBL] [Abstract][Full Text] [Related]
16. Promises and challenges in developing miRNA as a molecular diagnostic tool for lung cancer.
Cho WC
Expert Rev Mol Diagn; 2011 Nov; 11(8):763-6. PubMed ID: 22022936
[No Abstract] [Full Text] [Related]
17. [Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 2) Driver mutation and molecular-targeted therapy in lung cancer].
Maemondo M
Nihon Naika Gakkai Zasshi; 2014 Jun; 103(6):1314-21. PubMed ID: 25151796
[No Abstract] [Full Text] [Related]
18. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
van Waalwijk van Doorn-Khosrovani SB; Pisters-van Roy A; van Saase L; van der Graaff M; Gijzen J; Sleijfer S; Hoes LR; van Berge Henegouwen JM; van der Wijngaart H; van der Velden DL; van Werkhoven E; Retel VP; van Harten WH; Huitema ADR; Timmers L; Gelderblom H; Verheul HMW; Voest EE
Ann Oncol; 2019 May; 30(5):663-665. PubMed ID: 31038154
[No Abstract] [Full Text] [Related]
19. [Diagnosis for ALK positive non-small cell lung cancer].
Feng Q; Yang X; Lin D
Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):61-8. PubMed ID: 25676397
[TBL] [Abstract][Full Text] [Related]
20. Biomarker-Based Treatment Selection in Non-Small Cell Lung Cancer.
Akerley W
J Natl Compr Canc Netw; 2017 May; 15(5S):689-691. PubMed ID: 28515245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
